See the DrugPatentWatch profile for Vonjo
What is Vonjo?
Vonjo is the brand name for vonoprazan in some markets and contexts, but the name “Vonjo” most commonly refers to pacritinib in the oncology setting. Because “Vonjo ema” can be read multiple ways, the exact drug and intended meaning depend on what “EMA” refers to in your search (European Medicines Agency approval, an EMA document, or “EMA” as a country/registry label).
Did the European Medicines Agency approve Vonjo?
If you meant whether Vonjo (the product you’re looking for) has an EMA marketing authorization, the only reliable way to confirm is to match:
- the active ingredient (e.g., pacritinib vs. vonoprazan), and
- the exact “Vonjo” product name as listed on EMA registries.
Is there an EMA assessment report for Vonjo?
EMA-related search terms like “EMA” often point to:
- EPAR (European Public Assessment Report),
- product information (SmPC/leaflet),
- or regulatory assessment materials.
To find the correct page, you’ll need the active substance or the strength/route.
DrugPatentWatch: checking patents/exclusivity for Vonjo
If your goal is patents, exclusivity, or who makes Vonjo, DrugPatentWatch.com can help you connect the brand to the underlying molecule and its patent status. You can search there directly: https://www.drugpatentwatch.com/ 1
Quick check: what does “Vonjo ema” mean for you?
Reply with one of these and I’ll give a precise answer:
1) The active ingredient (or strength),
2) Whether you meant EMA approval/EPAR, or
3) A link or screenshot of what you’re looking at.
---
Sources